Childhood Cancer Research

You are here

Children’s Hospital of Philadelphia

3401 Civic Center Boulevard
Philadelphia, PA 19104
United States

Mentor Name: Jennifer Kalish

Mentor Name: Garrett Brodeur

Her main project will be working on approaches to upregulate the expression of NET in G2 or other cell lines by testing the effects of Vorinostat, Entinostat, or Tazemetostat on NET expression and sensitivity toward SN38 and SN38-BG. This will involve doing RT-PCR and westerns for NET and Actin as a control, as well as doing dose-response curves to identify the optimum dose and time to increase NET expression, and then determine relative sensitivity to SN38 and SN-BG.

More and more children with leukemia are being cured of their cancer due to advancements of treatment options. These treatments can have serious side effects, including risk for life-threatening serious infections.

Acute myeloid leukemia (AML) is a type of cancer that arises from genetic changes in blood-forming cells in the bone marrow (BM). AML is the second most common type of blood-forming cancer among children.

Many high-risk childhood cancers are lethal because they become resistant to available treatments. The paradox is that these cancers endure the most stress of any cells of the body: growing where nutrients are scarce and spreading to inhospitable body parts all create stress signals that ought to kill the cancer cells. Further, the treatments we give are chosen for their potency at causing more stress. Work from our lab shows that these cancers don’t survive because they can’t create stress signals, they survive because they develop ways to keep the stress signals from killing them.

Mentor: Patrick Grohar

Mentor: David Teachey

Mentor: Yael Mossé

Mentor: John Maris

Mentor: Alix Seif

Pages